Clinical trial · Interventional
A Trial of ZL-1201 in Subjects With Advanced Cancer
First in Human, Phase I Trial of ZL-1201 in Subjects With Advanced Cancer
NCT04257617CI-TRIAL-00068975completedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
First in Human, Phase I Trial of ZL-1201 in Subjects with Advanced Cancer
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Advanced Cancer | Malignant Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| ZL-1201 | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Single arm, ZL-1201
- description
- Single arm, ZL-1201
- interventionNames
- Drug: ZL-1201
Primary outcomes (1)
- measure
- Safety and tolerability of ZL-1201 when administered as an intravenous (IV) infusion: Incidence of Treatment-Emergent Adverse Events
- timeFrame
- From the time of informed consent to 30 days after last dose
- description
- Incidence of Treatment-Emergent Adverse Events as Assessed by CTCAE v5.0
Secondary outcomes (7)
- measure
- Pharmacokinetics：AUC
- timeFrame
- Up to 30 days after last dose
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically/cytologically confirmed, locally advanced unresectable or metastatic solid tumors and lymphomas that are refractory or intolerant to standard of care therapy, or for which no standard therapy exists. * Adequate hematologic status * Adequate coagulation function * Adequate hepatic function * Adequate renal function Exclusion Criteria: * Known active brain metastases * Red blood cells transfusion dependence * Known cardiopulmonary disease * Pregnant or breast-feeding females * Any other serious underlying medical
References
Publications (0)
Data not yet available
No reference posted for this study.